Hematology/Oncology

Top Story

Hereditary cancer foundation launches Lynch Syndrome patient registry

February 10, 2016

AliveAndKickn has announced the launch of the HEROIC Registry, a genetic database for people with Lynch Syndrome to share data and further research, according to a press release.

Lynch Syndrome, a hereditary disorder caused by a mismatch repair gene mutation that increases risk for colorectal, endometrial and other (often early-onset) cancers, is a CDC Tier 1 public health initiative genetic mutation, according to the press release. It affects one in 440 Americans, but up to 95% are undiagnosed.

In the Journals

Obesity linked to poor outcomes in acute promyelocytic leukemia

February 10, 2016
Obesity appeared significantly associated with shorter DFS and OS among adult patients with acute promyelocytic leukemia, according to a pooled analysis of four clinical…
FDA News

FDA places full clinical hold on pacritinib

February 10, 2016
The FDA has placed a full clinical hold on studies that involve pacritinib, an oral tyrosine kinase inhibitor in development for the treatment of patients with…
In the Journals

Palliative care reduces financial burden of patients with advanced cancer, comorbidities

February 10, 2016
The immediate initiation of palliative care among hospitalized patients with incurable cancers and chronic comorbid conditions resulted in significant hospital cost…
EditorialPublication Exclusive

The year of living dangerously

HemOnc Today, February 10, 2016
Derek Raghavan, MD, PhD
The turmoil of December and early January has died down, and I have had time to think about the upcoming year, which seems to offer the possibility of being a year that…
More News Headlines »
CME

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty-five percent of lung cancers are non-small…
More »
Video

VIDEO: Microsatellite instability predicts enhanced response to immunotherapy

February 4, 2016
More »
Featured
CME

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by an educational grant from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty five percent of lung cancers are non-small…
More »
Current Issues
View the Current Issue
HemOnc Today
morganatic-roan morganatic-roan